Free Trial

Hims & Hers Health (HIMS) Stock Forecast & Price Target

Hims & Hers Health logo
$30.87 -1.35 (-4.19%)
(As of 12/2/2024 ET)

Hims & Hers Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
8
Buy
7

Based on 16 Wall Street analysts who have issued ratings for Hims & Hers Health in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 1 has given a sell rating, 8 have given a hold rating, and 7 have given a buy rating for HIMS.

Consensus Price Target

$21.43
-30.58% Downside
According to the 16 analysts' twelve-month price targets for Hims & Hers Health, the average price target is $21.43. The highest price target for HIMS is $38.00, while the lowest price target for HIMS is $10.00. The average price target represents a forecasted downside of -30.58% from the current price of $30.87.
Get the Latest News and Ratings for HIMS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hims & Hers Health and its competitors.

Sign Up

HIMS Analyst Ratings Over Time

TypeCurrent Forecast
12/4/23 to 12/3/24
1 Month Ago
11/4/23 to 11/3/24
3 Months Ago
9/5/23 to 9/4/24
1 Year Ago
12/4/22 to 12/4/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$21.43$20.21$20.29$12.36
Forecasted Upside-30.58% Downside-0.72% Downside38.85% Upside39.15% Upside
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy
My most important prediction yet (Ad)

One year ago at this time, I was gearing up to do something I’d never done before… After years of working behind the scenes, helping Tom Busby and teaching traders all about the markets, I was about ready to jump in front of a camera. Why? Because my research and years of expertise were showing me a phenomenon that people NEEDED to know about. That gold was setting up to go on a historic run that I called the “2024 Gold Supercycle.” I went LIVE on December 7, 2023, and made my bold prediction — staking 20+ years of a reputation on this one public prognostication. And the rest, as they say, is history… Gold went on to have its best year since 1979 — almost half a century! I’m going to tell you all about it on Wednesday, December 4th @ 1:00 PM ET, 362 days after I first made my prediction on gold.

Go here and finish your registration to receive your access link

HIMS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HIMS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Hims & Hers Health Stock vs. The Competition

TypeHims & Hers HealthMedical CompaniesS&P 500
Consensus Rating Score
2.38
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-30.58% Downside25,883.38% Upside6.71% Upside
News Sentiment Rating
Positive News

See Recent HIMS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/2/2024Canaccord Genuity Group
1 of 5 stars
 Boost TargetBuy ➝ Buy$28.00 ➝ $38.00+12.69%
11/20/2024TD Cowen
5 of 5 stars
 Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00+25.39%
11/14/2024Bank of America
4 of 5 stars
 DowngradeBuy ➝ Underperform$32.00 ➝ $18.00-17.09%
11/6/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$23.00 ➝ $27.00+12.17%
11/5/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.00-3.14%
8/22/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Macdonald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$24.00+44.93%
8/9/2024Imperial Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Piccolo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ In-Line
7/18/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$13.00 ➝ $23.00+2.68%
6/27/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$14.00 ➝ $23.00+19.98%
5/22/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$16.00 ➝ $20.00+13.96%
4/26/2024Seaport Res Ptn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Kessler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/27/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$15.00 ➝ $17.00+22.83%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$10.00+5.04%
1/5/2024Tigress Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$14.00 ➝ $15.00+81.38%
8/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$14.00+77.22%
4/11/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$10.00+2.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:11 AM ET.


HIMS Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Hims & Hers Health is $21.43, with a high forecast of $38.00 and a low forecast of $10.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last year. There is currently 1 sell rating, 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HIMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HIMS, but not buy additional shares or sell existing shares.

According to analysts, Hims & Hers Health's stock has a predicted downside of -30.58% based on their 12-month stock forecasts.

Over the previous 90 days, Hims & Hers Health's stock had 1 downgrade by analysts.

Hims & Hers Health has been rated by research analysts at Bank of America, Canaccord Genuity Group, Deutsche Bank Aktiengesellschaft, Piper Sandler, and TD Cowen in the past 90 days.

Analysts like Hims & Hers Health less than other "medical" companies. The consensus rating for Hims & Hers Health is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HIMS compares to other companies.


This page (NYSE:HIMS) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners